Achema middle east

Vetter’s Peter Soelkner featured on the “Molecule to Market” podcast

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Celltrion Eyes Full-Scale Contract Manufacturing Operations

Celltrion on January 02, 2026, announced that it has...

CMS Unveils a New Voluntary Access Programme For GLP-1

In the most recent of a string of announcements ahead...

Bevacizumab to be Used by NHS for Colorectal Cancer

NICE has gone ahead and cleared the way for...
- Advertisement -

Peter Soelkner featured on the “Molecule to Market” podcast

Peter Soelkner, one of the managing directors at Vetter, recently sat down with Raman Sehgal of the “Molecule to Market” podcast to share his personal background, the history of Vetter, and the ambitious goals the company is striving towards today.

Listen to the episode in your podcast player:

Company: Vetter


Headquartered in Ravensburg, Germany, Vetter is a family-owned, global leading contract development and manufacturing organization (CDMO) with production facilities in Germany, Austria and the United States. Currently employing more than 5,700 individuals worldwide, the company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and enhanced compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.

Send Enquiry for this story

By submitting this form you agree to allow www.worldpharmatoday.com to contact you regarding your enquiry.
See our Privacy Policy to learn more.

Latest stories

Related stories

Celltrion Eyes Full-Scale Contract Manufacturing Operations

Celltrion on January 02, 2026, announced that it has...

CMS Unveils a New Voluntary Access Programme For GLP-1

In the most recent of a string of announcements ahead...

Bevacizumab to be Used by NHS for Colorectal Cancer

NICE has gone ahead and cleared the way for...

Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal

The French pharma giant, Sanofi, has started a $15.50...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »